ACMG |
American College of Medical Genetics and Genomics |
DICER1 |
Ribonuclease III; double-stranded RNA-specific endoribonuclease |
EMA |
European Medicines Agency |
FDA |
Food and Drug Administration |
HBOC |
hereditary breast and ovarian cancer syndrome |
HRD |
homologous recombination deficiency |
HRR |
homologous recombination repair |
ICI |
immune checkpoint inhibitor |
LEGH |
lobular endocervical glandular hyperplasia |
MDA |
minimal deviation adenocarcinoma |
MGP |
multi-gene panel |
MMR |
mismatch repair |
MRI |
magnetic resonance imaging |
MSI |
microsatellite instability |
MSI-H |
microsatellite instability-high |
MSI-L |
microsatellite instability-low |
MSS |
microsatellite stable |
NCCN |
National Comprehensive Cancer Network |
PARP |
poly ADP ribose polymerase |
PJS |
Peutz–Jeghers syndrome |
RRSO |
risk-reducing salpingo-oophorectomy |
SCAT |
sex-cord tumor with annular tubules |
VUS |
variant of uncertain significance |